Melanocortin interventions in cachexia: how soon from bench to bedside?
Melanocortin interventions in cachexia: how soon from bench to bedside?
复制标题
DOI：
10.1097/mco.0b013e328108f441
复制
发表时间：
2007-07-01
影响因子：
3.1
通讯作者：
DeBoer, Mark D.
中科院分区：
文献类型：
--
作者：
DeBoer, Mark D.
Purpose of reviewCachexia is a condition of anorexia and wasting that accomapnies many diseases including cancer, heart failure, and renal failure. One key center that is probably involved in the propagation of symptoms of cachexia is the melanocortin system in the hypothalamus and brainstem. This review focuses cachexia treatment interventions that act via melanocortin antagonism, by direct or indirect means.Recent findingsRecent reports include a description of the physiology of the melanocortin system and its responsiveness to inflammatory cytokine. Regarding treatment potential, multiple reports describe the effectiveness of small molecule antagonists of the melanocortin-4 receptor in animal models of cachexia. These melanocortin antagonists, given by peripheral injection, improve food intake and lean body mass retention in the setting of cancer and renal failure. Additional reports provide evidence of melanocortin antagonism following treatment of cachexia using ghrelin and eicosonic acidSummaryCahexia is a serious condition that accompanies various disease states and currently does not have effective treatments. The melanocortin system may play a direct role in producing symptoms of cachexia, making antagonism of this system a logical objective for ameliorating these symptoms. Thus far, however, no data on human application have been published.
